Navigation Links
Omeros to Present at Oppenheimer 24th Annual Healthcare Conference
Date:12/5/2013

SEATTLE, Dec. 5, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at the Oppenheimer 24th Annual Healthcare Conference in New York City next week.  The presentation is scheduled for Wednesday, December 11, 2013 at 1:35 p.m. EST.

The presentation will be webcast. The live and archived webcasts can be accessed on the "Events" page of the Company's website at www.omeros.com.  

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics targeting inflammation, coagulopathies and disorders of the central nervous system. Derived from its proprietary PharmacoSurgery® platform, the Company's lead drug product, OMS302 for lens replacement surgery, is currently under review for marketing approval by both the US Food and Drug Administration and the European Medicines Agency with commercial launch planned for 2014. Omeros' five other clinical programs are focused on schizophrenia, Huntington's disease and cognitive impairment; addictive and compulsive disorders; complement-related diseases; and preventing problems associated with surgical procedures. Omeros also has a proprietary GPCR platform, which is making available an unprecedented number of new GPCR drug targets and corresponding compounds to the pharmaceutical industry for drug development.


'/>"/>
SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Omeros Reports Phase 3 OMS302 Clinical Data Presented at the Annual American Academy of Ophthalmology Meeting
2. Omeros Announces Positive OMS721 Data in Model of Age-Related Macular Degeneration
3. FDA Grants Orphan Drug Designation to Omeros OMS824 for Huntingtons Disease
4. Omeros Chosen to Present at NewsMakers in the Biotech Industry 2013 Conference
5. Omeros Reports Initiation of Phase 2 Clinical Trial with OMS824
6. Omeros Reports Additional Positive Results from OMS824 Program
7. Omeros Submits OMS302 Marketing Authorization Application to European Medicines Agency
8. Omeros to Present at the Stifel Healthcare Conference 2013
9. Michael A. Jacobsen Joining Omeros as Vice President, Finance and Chief Accounting Officer
10. Omeros Corporation Reports Second Quarter 2013 Financial Results
11. Omeros to Present at the Wedbush 2013 Life Sciences Management Access Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 23, 2017 Report analyzes the ... provides separate comprehensive analytics for the US, Canada ... , Asia-Pacific , Latin ... forecasts are provided for the period 2015 through 2022. Also, ... data and analytics are derived from primary and secondary research. ...
(Date:2/24/2017)... , Feb. 23, 2017  Directors from Pharma To Market Pty ... have joined forces, resulting in the founding of Pharma To Market ... Pharma To Market are pleased to announce their expansion into ... Singapore . The company are delighted to appoint ... of the Singapore based entity. Joelle brings ...
(Date:2/24/2017)... Feb. 23, 2017  The particle counters market ... 2021 from USD 275.9 million in 2016, at ... full report: http://www.reportlinker.com/p04718602-summary/view-report.html The ... pharmaceutical R&D, and growth in manufacturing industries in ... growth for particle counters. On the other hand, ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... Only two months after ... Travel Market (ILTM) show in Cannes (France), XO Private has initiated a second print-run ... 420-page book measures almost a metre across when open, weighs in at more than ...
(Date:2/24/2017)... ... February 24, 2017 , ... Dr. Ronald E. ... announced the appointment of Peter A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as ... beginning April 10. Dr. Bell comes to Liberty from the Ohio University Heritage ...
(Date:2/24/2017)... , ... February 24, 2017 , ... ... hearing disabilities, it is so critically important that we all are aware of ... is why Mediaplanet is proud to announce the launch of its newest edition ...
(Date:2/24/2017)... ... February 24, 2017 , ... With ProGlass Prism users now have the ... have total control over position, rotation, distortion, edge softness, edge blur, chromatic aberration, individual ... X. , With ProGlass Prism users are given the tools and effects to ...
(Date:2/24/2017)... ... February 24, 2017 , ... The International Association of Eating Disorders ... Beyond What You See” body image mannequin art competition. Selected from 15 submissions from ... the winner revealed at the 31st annual iaedp Symposium, March 22 – 26 in ...
Breaking Medicine News(10 mins):